Emergency Use Authorization Granted to Ab-Cellera Antibody
Bamlanivimab, an antibody effective in treating mild to moderate COVID-19 cases in adults and pediatric patients over 12 years of age who are at a high risk of hospitalization, was released today (11/10) by Ab-Cellera. Following their Phase 2 clinical trial,...
Pfizer Reaches Breakthrough Results with COVID-19 Vaccine Candidate
Based on initial trial results, Pfizer’s vaccine candidate for COVID-19 has proven to be 90% effective in fighting the virus. Pfizer and their German partner BioNTech expect a regulatory decision for emergency use authorization as soon as...
Brilanta by AstraZeneca Approved to Reduce Risk of Stroke
Brilanta was approved by the U.S. Food and Drug Administration (FDA) for its efficacy in reducing the risk of stroke in patients with acute-ischemic stroke based on the Phase 3 THALES Trial. Compared to aspirin alone, when taken with Brilanta there was a clinically...
Merck Acquires Velosbio for $2.75 Billion for Promising Cancer Therapy
Today (11/5) Merck announced their all-cash acquisition of San Diego’s VelosBio following the release of Phase 1 data of ROR1 targeting VLS-101. VLS-101 is a drug for treatment of hematologic malignancies, and exited clinical trial Phase 1 with results showing...
Biogen is Hopeful for First Alzheimer’s Drug in 20 Years to be Approved by FDA
Biogen’s aducanumab has been praised before a final approval meeting by the U.S. Food and Drug Administration (FDA) to treat the disease that is the sixth leading case of death among 65+, Alzheimer’s. Biogen is expecting “blockbuster” sales of over $1 billion from the...
First-of-its-Kind HIV Self-Test Approved by Health Canada
BioLytical Laboratories has been approved for the commercial use of their at-home HIV self-test kit that yields 99% accuracy and takes about one minute to produce results to combat the rising HIV cases in Canada. The INSTI HIV Self-Test kit is BioLytical’s newest...